SEC Form 4 · accession 0001209191-15-003883
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David Altshuler
Officer — EVP, Global Research and CSO
Period of report
Jan 12, 2015
Accepted (ET)
Jan 13, 2015 · 4:14 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 12, 2015 | A | 75,000 | $0.01 | A | 75,000 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1Performance-based retention award that will vest if performance objectives are achieved prior to November 15, 2019. The award will vest on January 12, 2018 if the Company achieves positive EBITDA for the 12-month period ending September 30, 2017. Between January 13, 2018 and November 15, 2019, if the Company achieves positive EBITDA for a 12-month period ending on a calendar quarter, the award will vest on the day following the applicable earnings release.